16. Jul 2024 News CatalYm Announces New Financing of $150M to Support Broad Phase 2b Development Program for Visugromab
20. Jun 2024 News Tubulis Doses First Patient in Phase I/IIa Trial Investigating ADC Candidate TUB-040 in Ovarian Cancer and Lung Adenocarcinoma
26. Mär 2024 News Protembis Announces Completion of € 30 Million Series B Financing Round and the Addition of Keith D Dawkins MD to the Board of Directors